(Sharecast News) - Pfizer's phase three clinical trial for its Covid-19 vaccine candidate has encountered no safety problems even after over 12,000 volunteers had been administered a second dose.
The pharmaceutical giant also announced on Tuesday that it had enrolled the 30,000 subjects initially targeted and was now aiming to expand the trial to a further 14,000.
The company is developing the vaccine alongside Germany's BioNTech SE.
No safety concerns or adverse events had been reported thus far with fatigue the most common side effect.
A conclusive reading on the vaccine's efficacy is still expected by the end of October, Pfizer said, adding that the first review of efficacy will be conducted once 32 coronavirus cases had been detected among participants.
Regarding the possible timing of a possible Emergency Use Authorisation from the US Food and Drug administration, Pfizer chief executive officer, Albert Bourla, said it remained unclear.
(Sharecast News) - NCC Group: Canaccord upgrades to buy with a target price of 318p.